MYC regulates a complex biological program by transcriptionally activating and repressing
its numerous target genes. As such, MYC is a master regulator of many processes, including …

Histone-lysine N-methyltransferase 2D (KMT2D), also known as MLL4 and MLL2 in humans
and Mll4 in mice, belongs to a family of mammalian histone H3 lysine 4 (H3K4) …

Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose
debilitating effects on the developing child, and highlight the need for molecularly targeted …

Background International consensus recognises four medulloblastoma molecular
subgroups: WNT (MB WNT), SHH (MB SHH), group 3 (MB Grp3), and group 4 (MB Grp4) …

Extensive prior research focused on somatic copy-number alterations (SCNAs) affecting
cancer genes, yet the extent to which recurrent SCNAs exert their influence through …

Current therapies for medulloblastoma were introduced primarily in the 1980s and consist of
predominantly cytotoxic, nontargeted approaches. Mortality from medulloblastoma remains …

Precision oncology implies the ability to predict which patients will likely respond to specific
cancer therapies based on increasingly accurate, high‐resolution molecular diagnostics as …

Cancer drug screening in patient‐derived cells holds great promise for personalized
oncology and drug discovery but lacks standardization. Whether cells are cultured as …

Mammalian SWI/SNF (BAF) chromatin remodeling complexes orchestrate a diverse set of
chromatin alterations which impact transcriptional output. Recent whole-exome sequencing …

Loss or inactivation of the histone H3K27 demethylase UTX occurs in several malignancies,
including multiple myeloma (MM). Using an isogenic cell system, we found that loss of UTX …